Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Treatment of cancer is often improved if two or more drugs are used in combination. In animal
studies, the use of the combination of ON 01910.Na (a new, unapproved drug) and irinotecan or
oxaliplatin (two approved and extensively used anti-cancer drugs) gave better results against
tumor cells than the use of any of the single drugs alone. In addition, the use of the
combinations did not result in an increase of side effects. This clinical trial will
determine what is the highest dose of ON 01910.Na that can be given safely in combination
with either irinotecan or oxaliplatin in human patients.
Phase:
Phase 1
Details
Lead Sponsor:
Onconova Therapeutics, Inc.
Treatments:
Camptothecin Glycine Irinotecan ON 01910 Oxaliplatin